These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

89 related items for PubMed ID: 16817816

  • 1. Treatment with a thiazolidinedione increases eye protrusion in a subgroup of patients with type 2 diabetes.
    Dorkhan M, Lantz M, Frid A, Groop L, Hallengren B.
    Clin Endocrinol (Oxf); 2006 Jul; 65(1):35-9. PubMed ID: 16817816
    [Abstract] [Full Text] [Related]

  • 2. Effects of pioglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus.
    Sharma PK, Bhansali A, Sialy R, Malhotra S, Pandhi P.
    Clin Endocrinol (Oxf); 2006 Dec; 65(6):722-8. PubMed ID: 17121522
    [Abstract] [Full Text] [Related]

  • 3. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial.
    Umpierrez G, Issa M, Vlajnic A.
    Curr Med Res Opin; 2006 Apr; 22(4):751-9. PubMed ID: 16684436
    [Abstract] [Full Text] [Related]

  • 4. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
    Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Gravina A, Mereu R, Palumbo I, D'Angelo A, Cicero AF.
    Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
    [Abstract] [Full Text] [Related]

  • 5. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus.
    Kim HJ, Kang ES, Kim DJ, Kim SH, Ahn CW, Cha BS, Nam M, Chung CH, Lee KW, Nam CM, Lee HC.
    Clin Endocrinol (Oxf); 2007 Feb; 66(2):282-9. PubMed ID: 17224000
    [Abstract] [Full Text] [Related]

  • 6. The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia.
    Comaschi M, Corsi A, Di Pietro C, Bellatreccia A, Mariz S, COM06 Study Investigators.
    Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):373-9. PubMed ID: 17919894
    [Abstract] [Full Text] [Related]

  • 7. Effects of pioglitazone and metformin on intracellular lipid content in liver and skeletal muscle of individuals with type 2 diabetes mellitus.
    Teranishi T, Ohara T, Maeda K, Zenibayashi M, Kouyama K, Hirota Y, Kawamitsu H, Fujii M, Sugimura K, Kasuga M.
    Metabolism; 2007 Oct; 56(10):1418-24. PubMed ID: 17884455
    [Abstract] [Full Text] [Related]

  • 8. Comparison of the effects of pioglitazone and metformin on insulin resistance and hormonal markers in patients with impaired glucose tolerance and early diabetes.
    Eguchi K, Tomizawa H, Ishikawa J, Hoshide S, Numao T, Fukuda T, Shimada K, Kario K.
    Hypertens Res; 2007 Jan; 30(1):23-30. PubMed ID: 17460368
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P, Sitagliptin Study 019 Group.
    Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112
    [Abstract] [Full Text] [Related]

  • 10. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.
    Miyazaki Y, DeFronzo RA.
    Diabetes Obes Metab; 2008 Dec; 10(12):1204-11. PubMed ID: 18476983
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.
    Derosa G, D'Angelo A, Salvadeo SA, Ferrari I, Gravina A, Fogari E, Maffioli P, Cicero AF.
    Metabolism; 2008 Nov; 57(11):1552-7. PubMed ID: 18940393
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Tolerability outcomes of a multicenter, observational, open-label, drug-surveillance study in patients with type 2 diabetes mellitus treated with pioglitazone for 2 years.
    Grossman LD, Parlan G, Bailey AL, Yee G, Yu M, Chan JY.
    Clin Ther; 2009 Jan; 31(1):74-88. PubMed ID: 19243708
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Comparison of the effects of pioglitazone and metformin on hepatic and extra-hepatic insulin action in people with type 2 diabetes.
    Basu R, Shah P, Basu A, Norby B, Dicke B, Chandramouli V, Cohen O, Landau BR, Rizza RA.
    Diabetes; 2008 Jan; 57(1):24-31. PubMed ID: 17914032
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Effects of pioglitazone on serum fetuin-A levels in patients with type 2 diabetes mellitus.
    Mori K, Emoto M, Araki T, Yokoyama H, Lee E, Teramura M, Koyama H, Shoji T, Inaba M, Nishizawa Y.
    Metabolism; 2008 Sep; 57(9):1248-52. PubMed ID: 18702951
    [Abstract] [Full Text] [Related]

  • 20. Thiazolidinedione derivatives in type 2 diabetes mellitus.
    Tack CJ, Smits P.
    Neth J Med; 2006 Jun; 64(6):166-74. PubMed ID: 16788214
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.